Inclusion Criteria:

- Confirmed pathologically, 2)diagnosed by showing vascular enhancement of the lesion
on at least two imaging techniques, or 3) diagnosed by showing vascular enhancement
on a single technique if the AFP is greater than 200, in the setting of cirrhosis or
chronic hepatitis B without cirrhosis (EASL consensus conference guidelines).

- Either 1) the tumour must be unresectable, based on the opinion of an experienced
surgeon specializing in hepatic resection, or 2) the patient Phase II SBRT HCC 13
must be medically inoperable, or 3) extra-hepatic metastases must be present (making
hepatic surgery an inappropriate treatment option).

- Karnofsky performance status (KPS) > 60 (Appendix II)

- Age: 18 years or older. Both male & female patients of all races can be included in
this study. Female patients within reproductive years may not be, nor become,
pregnant during participation in this study

- Patients must have recovered from the effects of previous therapy.

- Maximal tumor size of 15 cm.

- Adequate organ function as assessed as follows:

- Hemoglobin > 90 g/L

- Absolute neutrophil count > 1.0 bil/L

- Platelets > 50 bil/L

- Bilirubin < 4.0 times upper range of normal

- INR < 1.5 or correctable with vitamin K (unless patient is on coumadin in which
case higher levels are acceptable)

- AST or ALT < 6.0 times upper range of normal

- Child's A 5-6 liver score or Child B 7-8 liver score, which is only permitted if the
maximal tumor size is 10 cm

- Previous liver resection or ablative therapy is permitted.

- Life expectancy > 3 months

- The volume of uninvolved must be at least 700 cc

- Up to five discrete liver tumors

- Patients must have signed a study-specific informed consent form. If the patient's
mental status precludes this, written informed consent may be given by the patient's
legal representative.

Exclusion Criteria:

- Patients with active hepatitis or encephalopathy related to liver failure

- Prior radiation therapy to the right upper abdomen, precluding reirradiation of the
liver. That is, any previous radiation therapy in which a mean dose to the liver of
15 Gy in conventional fractionation was delivered, or previous doses to critical
normal structures that would make re-irradiation unsafe. The PI should be called if
there is any question of safety of re-irradiation.

- Eligible for RFA or alcohol ablation

- Eligible for TACE

- Prior uncontrolled, life threatening malignancy within the six months.

- Pregnancy is not permitted, and in women of child bearing age, a pregnancy test and
acceptable methods of contraception are warranted.

- Previous gastric, duodenal or variceal bleed within the past 2 months.

- Commencement of coumadin use within the past 3 months.